Regulatory · Clinical · Site intelligence
Intune Bio brings FDA regulatory affairs, clinical study services and data-driven site selection under one team. Diagnostics and medical device companies get a single plan, and fewer surprises at every stage.
Each practice stands on its own. Together, regulatory strategy shapes study design, and study design shapes which sites you pick.
FDA pathway strategy, pre-submissions, 510(k), De Novo, CLIA Waiver and OTC filings for IVDs and devices.
Regulatory services →Analytical and clinical studies, designed to the protocols FDA expects and managed to budget.
Clinical services →Independent, explainable scoring of clinical sites, so you start with sites that activate fast and enroll.
Site intelligence →Regulatory Affairs
We start with the pathway, the predicate and the questions FDA will ask, so every study you run is one you actually need.
Discuss your submissionClinical Services
We design and run the analytical and clinical work your submission depends on, and we benchmark so you don’t overpay for it.
Plan your studySite Selection Intelligence
The Intune InSite Score is built from independent verification of what sites have actually done by cross-referencing trial registries and multiple data sources, not from what the sites claim they can do.
Each signal is weighted against your protocol and compared with similar sites and studies, so every site is measured the same way. Every score comes with its reasons and the risks to watch.
Why Intune Bio
Study scope follows from the regulatory plan, so you don’t pay for data FDA won’t ask for.
Clinical sites are picked with the same scoring we offer sponsors and CROs, not from a favorites list.
We compare consultants, CROs and labs stage by stage, so your budget reflects the market.
Proposals are priced per stage with clear decision points, so you commit one step at a time.
Your product, your stage and where you need help: regulatory, clinical, sites, or all three.
A plan priced stage by stage, with the decision points and benchmarks behind it.
We run the work with regular updates, and review each stage before the next begins.
Filing, FDA questions and, for ongoing studies, site rescue if enrollment slips.
No. Many clients start with one, such as a regulatory strategy or a site shortlist, and add others as the program moves forward.
Our regulatory work focuses on in vitro diagnostics and medical devices, including 510(k), De Novo, CLIA Waiver and OTC submissions.
We design and manage studies and work with qualified CROs, labs and clinical sites, chosen on evidence and benchmarked on cost.
No. It covers Phase I–IV therapeutics, vaccines, diagnostics and devices, including multi-region programs.
No. We work alongside CROs, adding regulatory direction, independent site scoring and cost benchmarks.
Non-confidential study inputs such as protocol parameters, regions and proposed sites. We do not request or store patient-level data.
Planning a submission, scoping a study or choosing sites? Send a few details and we’ll reply within one business day with next steps.
Prefer email? customercare@intune.bio
Intune Bio · 2265 E Foothill Blvd, Pasadena, CA 91107, USA